 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Nov 3 Calls Today's Calls |
| Call Details | |||
| Impax Laboratories Earnings Conference Call (Q3 2009) Tue, Nov 3, 2009, 11:00 am Eastern
| |||
| About Impax Laboratories (NasdaqGM:IPXL) | |||
| Impax Laboratories, Inc. engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates through two divisions, Global Pharmaceuticals and Impax Pharmaceutical. The Global Pharmaceuticals division develops, formulates, manufactures, and sells controlled release and specialty generic pharmaceutical products. This division offers generic prescription products directly to wholesalers and large retail drug chains; and generic over-the-counter and generic prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimer’s disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson’s disease, and schizophrenia. As of March 10, 2009, the company marketed 70 generic pharmaceuticals representing dosage variations of 24 different pharmaceutical compounds through its Global Pharmaceuticals division, as well as 16 products representing dosage variations of 4 different pharmaceutical compounds through its alliance agreements’ partners. Impax Laboratories markets and sells its generic pharmaceutical prescription drug products in the continental United States of America and the Commonwealth of Puerto Rico. It has alliance agreements with Teva Pharmaceutical Industries, Ltd.; Wyeth; Schering-Plough Corporation; and DAVA Pharmaceuticals, Inc. The company was founded in 1993 and is headquartered in Hayward, California. | |||
More Info: | |||
